Asia - South

China and the United Arab Emirates have seen some positive results in their Phase III COVID-19 vaccine trials, Chinese foreign ministry spokesman Wang Wenbin told a news briefing in Beijing on Wednesday.

China has four COVID-19 vaccines in the final stage of clinical trials. At least three of those have already been offered to essential workers under an emergency use programme launched in July.

As China publicly claims it is closing in on a coronavirus vaccine, Beijing has begun promising early access to countries of strategic interest.

With pledges of a coronavirus vaccine, China is on a charm offensive to repair strained diplomatic ties and bolster engagement with other countries.

China National Biotec Group (CNBG) and Sinovac Biotech said on Saturday (September 5) that four more countries have agreed to run late-stage human tests of their coronavirus vaccine candidates, as China steps up its efforts in the global race.

India is known as "the pharmacy of the world," and the nickname is well-deserved.

High-profile COVID-19 vaccines developed in Russia and China are based on a common cold virus.

Constitution of the Price Negotiation Board and implementing guidelines on price negotiation for new, innovative and single sourced health commodities.

Because Bangladesh enjoys the freedom from international intellectual proprietary regulations (patent) until 2032, local pharmaceutical companies can copy innovators' drugs almost immediately.

A Chinese pharmaceutical maker is in talks with several countries to get emergency approval to use an experimental Covid-19 vaccine, developed with the Chinese military.

CNBC's Eunice Yoon reports on how China is deploying a potential coronavirus vaccine by testing it on some essential workers.

The results of China’s latest round of drug procurement - a brutal price-cutting exercise.

Drugmakers have slashed prices by up to 95% to win state contracts in China's largest bidding round of its drug procurement programme.

Sinopharm has said its experimental vaccine could be ready for public use by the end of this year and cost no more than 1,000 yuan ($144.27) for two shots.

The drug costs up to Rs 7,000 in India and around 20,000 Nepal.